AKARI INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Akari Therapeutics, Plc To Contact The Firm

NEW YORK, May 12, 2017

The investigation focuses on whether the Company and its executives violated federal securities laws.  Specifically, on May 11, 2017, Akari filed a Form 6-K with the Securities and Exchange Commission announcing that Akari has established an ad hoc special committee to review the involvement of Company personnel regarding a report issued on April 26, 2017 by Edison Investment Research Inc., an investment research and advisory company. Furthermore, the Form 6-K disclosed that Dr. Gur Roshwalb, the Company's Chief Executive Officer, has been placed on administrative leave while the review is pending.

As a result, the price of Akari's American Depositary Receipts ("ADRs") declined significantly, causing harm to investors.

If you invested in Akari ADRs and would like to discuss your legal rights, click here: www.faruqilaw.com/AKTX. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26^th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.